We are live on ! Find out more
COCP icon

Cocrystal Pharma
COCP

20 hedge funds and large institutions have $1.59M invested in Cocrystal Pharma in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more capital invested

Capital invested by funds: $1.47M → $1.59M (+$126K)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

2.52% less ownership

Funds ownership: 9.08% → 6.56% (-2.5%)

5% less funds holding

Funds holding: 21 → 20 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
20
Holders Change
-1
Holders Change %
-4.76%
% of All Funds
0.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
4
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$11.4K
2
JP Morgan Chase
JP Morgan Chase
New York
+$491
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$211
4
Wells Fargo
Wells Fargo
California
+$36

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$132K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$14.2K
3
TRCT
Tower Research Capital (TRC)
New York
-$7.38K
4
UBS Group
UBS Group
Switzerland
-$4.17K
5
Morgan Stanley
Morgan Stanley
New York
-$586
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$649K – – –
Renaissance Technologies
2
Renaissance Technologies
New York
$298K +$11.4K +4,700 +4%
BlackRock
3
BlackRock
New York
$177K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$166K – – –
Morgan Stanley
5
Morgan Stanley
New York
$106K -$586 -241 -0.5%
State Street
6
State Street
Massachusetts
$58.4K – – –
PA
7
Parallel Advisors
California
$36.4K – – –
Susquehanna International Group
8
Susquehanna International Group
Pennsylvania
$35.6K -$14.2K -5,831 -28%
Northern Trust
9
Northern Trust
Illinois
$29.2K – – –
Bank of America
10
Bank of America
North Carolina
$21.4K – – –
TRCT
11
Tower Research Capital (TRC)
New York
$13.4K -$7.38K -3,038 -35%
JP Morgan Chase
12
JP Morgan Chase
New York
$1.08K +$491 +202 +80%
CYG
13
Clean Yield Group
Vermont
$999 – – –
UBS Group
14
UBS Group
Switzerland
$660 -$4.17K -1,716 -86%
Wells Fargo
15
Wells Fargo
California
$241 +$36 +15 +17%
Fidelity Investments
16
Fidelity Investments
Massachusetts
$217 +$211 +87 +2,175%
AIC
17
Archer Investment Corporation
Indiana
$201 – – –
NL
18
NVWM LLC
Pennsylvania
$201 – – –
Osaic Holdings
19
Osaic Holdings
Arizona
$5 – – –
SM
20
Sabby Management
Florida
– -$132K -66,172 Closed

COCP Hedge Fund Activity: Q2 2023 in Review

20 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q2 2023, worth a combined $1.59M — up 8.6% from $1.47M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of COCP and 0 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.

The largest buyer was Renaissance Technologies, adding an estimated $11.4K. The largest seller was Sabby Management, exiting entirely with an estimated $132K sold.

  • 20 institutional investors held Cocrystal Pharma (COCP) as of Q2 2023, down from 21 in Q1 2023.
  • Funds reported $1.59M of Cocrystal Pharma stock for Q2 2023, up 8.6% quarter-over-quarter.
  • 0 funds opened new Cocrystal Pharma positions in Q2 2023 and 1 closed out, a net change of -1 holder.
  • The largest Cocrystal Pharma buyer in Q2 2023 was Renaissance Technologies, an estimated $11.4K added.
  • The largest Cocrystal Pharma seller in Q2 2023 was Sabby Management, an estimated $132K sold.

Based on aggregated 13F filings for Q2 2023.